Lucira Health (LHDXQ) Stock Price, News & Analysis

Company Overview

Lucira Health, Inc. is a developer of rapid molecular diagnostic tests designed for use in home and point-of-care settings. Headquartered in Emeryville, California, the company leverages proprietary reverse transcription–loop-mediated isothermal amplification (RT-LAMP) technology to deliver single-use, instrument-free assays. Its flagship product, the Lucira COVID-19 All-In-One Test Kit, enables users to collect a nasal swab sample, run the test on-site and obtain results in under 30 minutes without the need for a laboratory.

In December 2020, Lucira Health received emergency use authorization (EUA) from the U.S. Food and Drug Administration for its COVID-19 test kit. The company rapidly expanded commercial availability through partnerships with national pharmacy chains, online retailers and direct-to-consumer channels, making at-home molecular testing broadly accessible across the United States. Lucira’s platform is inherently adaptable, and the company has signaled plans to pursue additional respiratory pathogen assays as regulatory approvals and market demand evolve.

While primarily serving the North American market, Lucira Health has explored distribution opportunities in select international regions and continues to seek regulatory clearances abroad. The company’s management team draws on extensive experience in diagnostics, consumer health and medical device commercialization, underscoring its commitment to advancing accessible, high-performance testing solutions that reduce dependency on centralized laboratory infrastructure.

Key Stats

• Today's Range: $0.0001 to $0.0001
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $1.45
• Volume: 20,900 shs
• Average Volume: 7.18 million shs
• Market Capitalization: $4.06 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

LHDXQ Stock Analysis - Frequently Asked Questions

How have LHDXQ shares performed this year?

Lucira Health's stock was trading at $0.0001 at the beginning of the year. Since then, LHDXQ stock has increased by 0.0% and is now trading at $0.0001.

How were Lucira Health's earnings last quarter?

Lucira Health, Inc. (OTCMKTS:LHDXQ) announced its quarterly earnings data on Thursday, November, 11th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.04. The business earned $14.98 million during the quarter, compared to the consensus estimate of $18 million.

How do I buy shares of Lucira Health?

Shares of LHDXQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 11/11/2021
• Today: 9/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:LHDXQ
• CIK: 1652724
• Web: www.lucirahealth.com
• Phone: 510-350-8071
• Fax: N/A
• Employees: 221
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $93.06 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.81 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 40,600,000
• Free Float: 28,257,000
• Market Cap: $4.06 thousand
• Optionable: Not Optionable
• Beta: 2.60